Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

Lymphoma Clinical Trial

— MAC UCBT  

Official title:

Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02310997
• Other study ID #: UCL/09/0128
• Secondary ID: 2009-011818-21
• Status: Terminated
• Phase: Phase 2
• First received: September 18, 2014
• Last updated: May 26, 2015
• Start date: July 2011
• Est. completion date: May 2015

Study information

• Verified date: May 2015
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).

The trial is for babies over 4 weeks old, children, and adults up to the age of 45.

Description:

During treatment for cancers of the bone marrow or lymphatic system, a lot of the stem cells are damaged and you may need a bone marrow or stem cell transplant to replace them.

Stem cells can also be collected from the umbilical cord of newborn babies. Many people around the world have donated their baby's umbilical cords which are stored safely.

There are usually enough cells in one cord to transplant a small child, but there may not be enough cells for an older child or adult. Researchers want to see if adults and children can safely have stem cells from more than 1 umbilical cord.

Before a transplant, you have high doses of chemotherapy, sometimes with radiotherapy. This intensive conditioning aims to destroy all the cells in your bone marrow, and is called myeloablative conditioning.

The aim of this trial is to see if a transplant using cord blood cells from unrelated donors after myeloablative conditioning is safe, and whether it helps people who need a stem cell transplant but don't have a stem cell donor.

You may be able to enter this trial if you:

• Have leukaemia, lymphoma or another disorder of the bone marrow and treatment with intensive conditioning followed by a stem cell transplant is likely to help you

• Do not have a suitable stem cell donor in your family, and your doctors have not been able to find a matched unrelated donor

• Have satisfactory blood test results

• Are between 4 weeks and 45 years old

You cannot enter this trial if you:

• Have a family member who could donate stem cells to you, or you have a matched unrelated donor

• Can have any other treatment that your doctors think will cure your disease or keep it under control for a long time

• Have already had a lot of radiotherapy (the trial doctor can advise you about this)

• Have already had a bone marrow or stem cell transplant using your own cells

• Have chronic myeloid leukaemia that is in chronic phase and is responding to imatinib, or is in blast phase and is not responding to treatment Have acute lymphoblastic leukaemia that is not responding to treatment or has come back and more than 5% of your bone marrow is made up of immature cells (blasts)

• Have acute myeloid leukaemia that is not responding to treatment or has come back and more than 20% of your bone marrow is made up of immature cells (blasts)

• Have a disease that has come back and you are having another type of treatment (salvage treatment) but your disease is not responding or is getting worse

• Have a blood disorder called myelofibrosis

• Have a blood disorder called aplastic anaemia

• Have an infection that cannot be controlled with medication

• Have either the HIV or HTLV virus

• Are pregnant or breastfeeding

This phase 2 trial aims to recruit 60 people. It will include both adults and children. Everybody taking part will have intensive conditioning before having a transplant of stem cells from the umbilical cord blood of at least 1 unrelated donor.

To take part in this trial, the researchers need to be sure that there are 2 lots of cord blood cells that would be suitable for you. They will only use cells from 2 cords if there is some concern that they won't get enough cells from 1 umbilical cord.

People aged between 2 and 45 (apart from children under the age of 16 who have acute myeloid leukaemia, juvenile myelomonocytic leukaemia (JMML) or MDS) will have conditioning with fludarabine, cyclophosphamide and radiotherapy to the whole body (total body irradiation). This takes 9 days all together. On the last day, you have the stem cells through a drip into a vein.

Children under 2 years of age (and children up to the age of 16 who have acute myeloid leukaemia, JMML or MDS) will have conditioning with busulfan, cyclophosphamide and melphalan. They do not have radiotherapy. This conditioning takes 10 days all together. They have the stem cells through a drip into a vein on the 11th day.

The stem cells find their way into your bone marrow where they will start making new blood cells.

You will see the trial team and have some tests before you start treatment. The tests include:

• Physical examination

• Blood tests

• Chest X-ray

• Lung function tests

• Heart trace (ECG)

• Heart ultrasound (echocardiogram) or MUGA scan

• Bone marrow test When you have your treatment, you will be in hospital for about 4 to 6 weeks. As you will be at a high risk of infection, you will be in your own room. This is called being in isolation. You have another bone marrow test a month after your transplant.

When you go home, you have to go back to the hospital for regular blood tests. This is likely to be 2 or 3 times a week to begin with. You may have to go back into hospital for a few days at some point.

After a transplant, you will see the doctors and have blood tests At least once a week for the first 3 months At least once a month for the rest of the first year The trial doctors will follow your progress closely for at least 2 years.

The main side effect of the treatment you have just before the transplant is a drop in the number of blood cells, causing an increased risk of infection, tiredness and breathing problems.

We have more information about fludarabine, cyclophosphamide, busulfan and melphalan in our cancer drugs section.

It takes longer for blood cells to start growing again after a transplant of cord blood than after other types of stem cell transplant. Even when your blood count gets back to normal, your immune system may take up to 2 years to recover fully.

Unfortunately, this treatment can affect your ability to have children (your fertility). Men taking part will be offered the option to store sperm (sperm banking) before starting treatment. Preserving fertility for women is more complicated and it is important that women talk to their doctors about this before starting treatment.

After any type of bone marrow or stem cell transplant, there is a risk of graft versus host disease (GVHD). This happens when the new stem cells attack your body tissue. It mainly affects your skin, gut and liver.

Rarely, the new stem cells fail to start working. This is more common with cord blood transplants than with other bone marrow transplants. And even if your transplant is successful, there is a risk your disease may come back. Because of these risks, your doctors will monitor you very closely after your transplant.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 45 Years

Eligibility

Inclusion Criteria:

• Subjects must be < 45 years of age and = 28 days old

• Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective

• The individual patient's disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival

• Left ventricular ejection fraction >45%

• Transaminases and bilirubin < twice the upper limit of the normal range

• Creatinine clearance > 60mls/min

• Comorbidity index of 0 or 1

Exclusion Criteria:

• Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor available within an acceptable time period.

• Pregnancy or breastfeeding.

• Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology

• Current active serious infection, in particular uncontrolled fungal infection -Previous irradiation that precludes the safe administration of an additional dose of 13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years

• Prior autograft

• CML in first chronic phase responding to Imatinib or refractory blast crisis

• Patients with acute leukaemia in morphological relapse/ persistent disease (defined as > 5% blasts in normocellular bone marrow)

• Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to re-induction chemotherapy (defined as >20% blasts in normocellular bone marrow)

• Malignant disease that is refractory to or progressive on salvage therapy

• Myelofibrosis.

• Aplastic anaemia

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukaemia
• Lymphoma
• Other Haematological Diseases

Intervention

Other:
• Umbilical Cord Blood Transplant

Drug:
• Cyclophosphamide

Radiation:
• Total body irradiation

Drug:
• Busulfan

• Melphalan

• Fludarabine

Locations

Country	Name	City	State
United Kingdom	University Hospital Birmingham	Birmingham
United Kingdom	Bristol Haematology & Oncology Centre	Bristol
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	St James' University Hospital	Leeds
United Kingdom	Great Ormond Street Hospital for Children	London
United Kingdom	St Bartholomew's Hospital	London
United Kingdom	University College London Hospital	London	Greater London
United Kingdom	Christie Hospital NHS Foundation Trust	Manchester
United Kingdom	Manchester Royal Infirmary	Manchester
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Royal Hallamshire Hospital	Sheffield
United Kingdom	Royal Marsden Hospital	Sutton

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-relapse mortality at 100 days post transplant		100 days post transplant	Yes
Secondary	Overall survival at 1 year		1 year post transplant	Yes
Secondary	Time course of mixed chimerism established by the donor graft		28, 60, 100 days, 6 months, 1 year post transplant	No
Secondary	Recovery from neutropenia and cytopenia		up to 1 year post transplant	Yes
Secondary	Incidence of acute and chronic GVHD		100 Days and 1 year post transplant	Yes
Secondary	Incidence of relapse		1 year post transplant	No